Asset Management One Co. Ltd. Raises Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Asset Management One Co. Ltd. lifted its stake in Edwards Lifesciences Co. (NYSE:EW) by 0.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 239,392 shares of the medical research company’s stock after acquiring an additional 2,188 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Edwards Lifesciences were worth $15,797,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. National Pension Service lifted its holdings in Edwards Lifesciences by 9.2% in the third quarter. National Pension Service now owns 1,584,579 shares of the medical research company’s stock valued at $104,566,000 after acquiring an additional 133,182 shares during the period. Forum Financial Management LP purchased a new stake in shares of Edwards Lifesciences during the 3rd quarter valued at about $203,000. Van ECK Associates Corp lifted its stake in shares of Edwards Lifesciences by 7.7% in the 3rd quarter. Van ECK Associates Corp now owns 126,764 shares of the medical research company’s stock worth $8,951,000 after purchasing an additional 9,011 shares during the period. Baxter Bros Inc. boosted its holdings in shares of Edwards Lifesciences by 1.8% in the third quarter. Baxter Bros Inc. now owns 85,268 shares of the medical research company’s stock worth $5,627,000 after buying an additional 1,510 shares during the last quarter. Finally, Invesco LLC grew its position in Edwards Lifesciences by 14.1% during the third quarter. Invesco LLC now owns 3,469 shares of the medical research company’s stock valued at $229,000 after buying an additional 430 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the sale, the insider now owns 198,526 shares in the company, valued at approximately $13,084,848.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total value of $1,647,750.00. Following the completion of the sale, the insider now owns 198,526 shares of the company’s stock, valued at $13,084,848.66. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were sold at an average price of $69.51, for a total value of $347,550.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,262,521.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 41,250 shares of company stock worth $2,746,988. 1.27% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Morgan Stanley reiterated an “equal weight” rating and issued a $70.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 11th. The Goldman Sachs Group cut their price target on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a report on Friday, July 26th. Truist Financial lowered their price objective on Edwards Lifesciences from $71.00 to $70.00 and set a “hold” rating on the stock in a research report on Friday, October 25th. Daiwa America lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 30th. Finally, StockNews.com lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Edwards Lifesciences has a consensus rating of “Hold” and a consensus target price of $75.67.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $66.69 on Wednesday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. The firm’s fifty day moving average is $67.81 and its 200 day moving average is $77.26. The company has a market cap of $40.17 billion, a price-to-earnings ratio of 9.62, a PEG ratio of 3.80 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last announced its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.67. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 22.56%. The business’s revenue was up 8.9% compared to the same quarter last year. During the same period in the prior year, the company earned $0.59 EPS. Sell-side analysts forecast that Edwards Lifesciences Co. will post 2.57 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.